Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antimicrobial final monograph may blend FDA, industry approaches -- agency's Lumpkins.

This article was originally published in The Rose Sheet

Executive Summary

ANTIMICROBIAL PRODUCTS FINAL MONOGRAPH MAY BLEND FDA, INDUSTRY APPROACHES to the regulation of products that contain antimicrobial ingredients, FDA Division of OTC Drug Product's Debbie Lumpkins predicted at a June 2-3 symposium in Washington, D.C. on industry's Health Care Continuum Model. The regulatory review microbiologist forecast that the final reg would take a "blended approach" combining "some of the HCCM [and] some of the TFM." The symposium was sponsored jointly by the Cosmetic, Toiletry and Fragrance Association and the Soap and Detergent Association.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel